Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 401–500 of 1,000
Todenhöfer, T., Stenzl, A., Hofbauer, L. C., & Rachner, T. D. (2015) · International Journal of Endocrinology · doi:10.1155/2015/838202 · Cited by 36
Kim, K. M., Lim, S. K., Moon, J. H., Jin, H., Jung, K. Y., Shin, C. S., Park, K. S., Jang, H. C., & Choi, S. H. (2015) · Bone · doi:10.1016/j.bone.2015.11.008 · Cited by 34
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 38
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures
Kim, B., Lee, S. H., & Koh, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.55 · Cited by 37
Regional improvements in lumbosacropelvic Hounsfield units following teriparatide treatment.
Flanigan, P., Mikula, A., Peters, P. A., Oushy, S., Fogelson, J. L., Bydon, M., Freedman, B., Sebastian, A. S., Currier, B., Nassr, A., et al. (2020) · Neurosurgical Focus · doi:10.3171/2020.5.focus20273 · Cited by 27
Davidson, G. R. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_526 · Cited by 39
Masuda, S., Fukasawa, T., Matsuda, S., Yoshida, S., & Kawakami, K. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07255-6 · Cited by 36
Romosozumab for the treatment of osteoporosis – a systematic review
Mäkinen, V.-N., Sølling, A. S., McClung, M. R., & Langdahl, B. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02469-1 · Cited by 36
Self-citationBone Metabolism in Anorexia Nervosa
Fazeli, P. K., & Klibanski, A. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0186-8 · Cited by 40
Perspectives on osteoporosis therapies
Cairoli, E., Zhukouskaya, V. V., Eller-Vainicher, C., & Chiodini, I. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0236-9 · Cited by 32
Emerging therapies in bone metastasis
Clément-Demange, L., & Clézardin, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.04.004 · Cited by 32
Huang, S., Zhu, X., Xiao, D., Zhuang, J., Liang, G., Liang, C., Zheng, X., Yu-hong, K., & Chang, Y. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1499-9 · Cited by 37
The Genetic Architecture of High Bone Mass
Gregson, C. L., & Duncan, E. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.595653 · Cited by 35
Holdsworth, G., Staley, J. R., Hall, P., van Koeverden, I. D., Vangjeli, C., Okoye, R., Boyce, R. W., Turk, J. R., Armstrong, M., Wolfreys, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4287 · Cited by 33
Ebina, K., Etani, Y., Tsuboi, H., Nagayama, Y., Kashii, M., Miyama, A., Kunugiza, Y., Hirao, M., Okamura, G., Noguchi, T., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06386-y · Cited by 32
Morse, A., Schindeler, A., McDonald, M. M., Kneissel, M., Krämer, I., & Little, D. G. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3330 · Cited by 35
Cardinal, M., Dessain, A., Roels, T., Lafont, S., Ominsky, M. S., Devogelaer, J., Chappard, D., Mabilleau, G., Ammann, P., Behets, C., et al. (2020) · Calcified Tissue International · doi:10.1007/s00223-019-00655-5 · Cited by 32
Lau, E. M. C., Dinavahi, R. V., Woo, Y. C., Wu, C., Guan, J., Maddox, J., Tolman, C., Yang, W., & Shin, C. S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05324-0 · Cited by 32
Self-citationCurrent therapeutic approach of chronic kidney disease‐mineral and bone disorder
Zaimi, M., & Grapsa, E. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14177 · Cited by 41
Fractures in chronic kidney disease
Goldenstein, P. T., Jamal, S. A., & Moysés, R. M. A. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000131 · Cited by 31
Relationship between Fetuin A, Vascular Calcification and Fracture Risk in Dialysis Patients
Chen, H. Y., Chiu, Y., Hsu, S. P., Pai, M., Yang, J., & Peng, Y. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158789 · Cited by 32
Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know
Delanaye, P., Paquot, F., Bouquegneau, A., Blocki, F. A., Krzesinski, J.-M., Evenepoel, P., Pottel, H., & Cavalier, E. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx282 · Cited by 31
Fontalis, A., Kenanidis, E. I., Kotronias, R. A., Papachristou, A., Anagnostis, P. G., Potoupnis, M. E., & Tsiridis, E. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594772 · Cited by 33
Tian, A., Jia, H., Zhu, S., Lü, B., Li, Y., Ma, J., & Ma, X. (2021) · Orthopaedic Surgery · doi:10.1111/os.13136 · Cited by 33
Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis
Martínez‐Gil, N., Ugartondo, N., Grinberg, D., & Balcells, S. (2022) · Genes · doi:10.3390/genes13010138 · Cited by 37
New Genetic Forms of Childhood-Onset Primary Osteoporosis
Kämpe, A. J., Mäkitie, R. E., & Mäkitie, O. (2015) · Hormone Research in Paediatrics · doi:10.1159/000439566 · Cited by 32
Bauer, D. C., Black, D. M., Dell, R., Fan, B., Smith, C., Ernst, M. T., Jurik, A. G., Frøkjær, J. B., Boesen, M., Vittinghoff, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae023 · Cited by 35
Emerging Therapies for Osteoporosis
McClung, M. R. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.429 · Cited by 30
Self-citationBone markers and osteoporosis therapy
Bandeira, F. A. F., Costa, A. G., Filho, M. A. S., Pimentel, L., Lima, L., & Bilezikian, J. P. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003384 · Cited by 37
A Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.003 · Cited by 33
Kashii, M., Ebina, K., Kitaguchi, K., & Yoshikawa, H. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100288 · Cited by 30
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
Poole, K. E. S., Treece, G. M., Pearson, R. A., Gee, A. H., Bolognese, M. A., Brown, J. P., Goemaere, S., Grauer, A., Hanley, D. A., Mautalén, C., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4465 · Cited by 30
Self-citationTakashi, Y., & Kawanami, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042376 · Cited by 33
Riancho, J., Peris, P., González-Macías, J., & Pérez-Castrillón, J.-L. (2022) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2022000100003 · Cited by 47
Bone Disease in Multiple Myeloma
Eda, H., Santo, L., Roodman, G. D., & Raje, N. S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_14 · Cited by 33
Everts‐Graber, J., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Sromek, K., Schmid, G., Gahl, B., Häuselmann, H., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07155-9 · Cited by 29
Cosman, F., Oates, M. K., Betah, D., Timoshanko, J., Wang, Z., Ferrari, S., & McClung, M. R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae116 · Cited by 32
Self-citationNovel approaches to the treatment of osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.07.003 · Cited by 35
Tinsley, B. A., Dukas, A. G., Pensak, M. J., Adams, D. J., Tang, A., Ominsky, M. S., Ke, H. Z., & Lieberman, J. R. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.o.00171 · Cited by 31
Sato, T., Verma, S. K., Khatri, A., Dean, T., Göransson, O., Gardella, T. J., & Wein, M. N. (2020) · JBMR Plus · doi:10.1002/jbm4.10441 · Cited by 29
Chiloiro, S., Frara, S., Gagliardi, I., Bianchi, A., Giampietro, A., Medici, M., Allora, A., di Filippo, L., Ambrosio, M. R., Pontecorvi, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad493 · Cited by 30
New bone-forming treatments for osteoporosis
Papapoulos, S. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.214 · Cited by 31
Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton
Sugiyama, T., Kim, Y. T., & Oda, H. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2923-y · Cited by 30
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease
Lundquist, A. L., & Nigwekar, S. U. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000203 · Cited by 32
Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Pazianas, M., & Abrahamsen, B. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13166 · Cited by 29
N‐cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage–Specific
Fontana, F., Hickman‐Brecks, C. L., Salazar, V. S., Revollo, L., Abou‐Ezzi, G., Grimston, S. K., Jeong, S. Y., Watkins, M. P., Fortunato, M., Alippe, Y., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3112 · Cited by 30
Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study
Resulaj, M., Polineni, S. P., Meenaghan, E. M., Eddy, K. T., Lee, H., & Fazeli, P. K. (2019) · JBMR Plus · doi:10.1002/jbm4.10251 · Cited by 31
Mechanisms Underlying Medication‐Related Osteonecrosis of the Jaw
Lee, K., Kim, K., Kim, J. Y., Kim, J., Kang, Y., Kim, Y. H., & Kim, S. (2024) · Oral Diseases · doi:10.1111/odi.15198 · Cited by 37
Wong, P. D., Chen, W., Ewald, D. P., Girgis, C. M., Rawlin, M., Tsingos, J., & Waters, J. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52637 · Cited by 50
Current and future treatments of osteoporosis in men
Kaufman, J., Lapauw, B., & Goemaere, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.002 · Cited by 30
Baek, K., Chung, Y., Koh, J., Kim, I. J., Kim, K. M., Min, Y., Park, K. D., Dinavahi, R. V., Maddox, J., Yang, W., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.848 · Cited by 34
Self-citationPrevalence of vertebral fractures and serum sclerostin levels in acromegaly
Uygur, M. M., Yazıcı, D., Buğdaycı, O., & Yavuz, D. G. (2021) · Endocrine · doi:10.1007/s12020-021-02751-9 · Cited by 31
Lu, J., Hu, D., Ma, C., & Shuai, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.938447 · Cited by 34
Simic, M. K., Mohanty, S. T., Xiao, Y., Cheng, T. L., Taylor, V. E., Charlat, O., Croucher, P. I., & McDonald, M. M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4809 · Cited by 29
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease
Iwasaki, Y., Kazama, J. J., & Fukagawa, M. (2017) · BioMed Research International · doi:10.1155/2017/3485785 · Cited by 33
Established and forthcoming drugs for the treatment of osteoporosis
Lems, W. F., & Geusens, P. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000057 · Cited by 28
Osteoporosis Therapy: Bone Modeling during Growth and Aging
Sugiyama, T., & Oda, H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00046 · Cited by 28
Anabolic Therapy for the Treatment of Osteoporosis in Childhood
Ward, L. M., & Rauch, F. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0434-z · Cited by 28
Leanza, G., Fontana, F., Lee, S.-Y., Remedi, M. S., Schott, C., Ferron, M., Hamilton-Hall, M. N., Alippe, Y., Strollo, R., Napoli, N., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4303 · Cited by 30
Taipaleenmäki, H., Saito, H., Schröder, S., Maeda, M., Mettler, R., Ring, M., Rollmann, E., Gasser, A. S., Haasper, C., Gehrke, T. A., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202013617 · Cited by 28
Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse
Sun, W., Shi, Y., Lee, W., Lee, S.-Y., & Long, F. (2016) · Bone · doi:10.1016/j.bone.2016.01.013 · Cited by 28
Bone repair with skeletal stem cells: rationale, progress to date and clinical application
Jones, E., Giannoudis, P. V., & Kouroupis, D. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16642372 · Cited by 29
Liu, X., Chin, J. F., Qu, X., Bi, H., Liu, Y., Yu, Z., Zhai, Z., Qin, A., Zhang, B., & Dai, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00627 · Cited by 29
Romosozumab to rebuild the foundations of bone strength
Ferrari, S. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.5 · Cited by 27
Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption
Tang, C.-C., Castro, C. D., O’Meara, M. J., Yoon, S.-H., Sato, T., Brooks, D. J., Bouxsein, M., Martins, J. D. S., Wang, J., Gray, N. S., et al. (2021) · eLife · doi:10.7554/elife.67772 · Cited by 29
Hong, N., Shin, S., Kim, H.-J., Cho, S., Park, J., & Rhee, Y. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae179 · Cited by 27
Sequential and Long-term Therapy for Osteoporosis
McClung, M. R. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00909-2 · Cited by 30
Self-citationBone marrow adipocytes: key players in vascular niches, aging, and disease
Fan, Y., El-Khalek, M. K. A., Zhang, Y., Liu, L., Tian, Q., Chueakula, N., Ramasamy, S. K., Dalan, R., Habib, S. J., & Kusumbe, A. P. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1633801 · Cited by 30
Peng, J., Zhang, D., Zhang, H., Aifei, W., Lianfu, D., & Xu, Y. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04365-8 · Cited by 29
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
Aditya, S., & Rattan, A. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_106_20 · Cited by 30
The effect of osteoporosis treatment on bone mass
Appelman‐Dijkstra, N. M., Oei, H. L. D. W., Veldhuis‐Vlug, A. G., & Winter, E. M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101623 · Cited by 30
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., & Okazaki, K. (2022) · Modern Rheumatology · doi:10.1093/mr/roac059 · Cited by 27
Basha, G., Cottle, A. G., Pretheeban, T., Chan, K. Y. T., Witzigmann, D., Young, R. N., Rossi, F. M. V., & Cullis, P. R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.012 · Cited by 29
Kotake, K., Mitsuboshi, S., Omori, Y., Kawakami, Y., & Kawakami, Y. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221144960 · Cited by 26
From the Mind to the Spine: The Intersecting World of Alzheimer’s and Osteoporosis
Margetts, T. J., Wang, H. S., Karnik, S. J., Plotkin, L. I., Movilă, A., Oblak, A. L., Fehrenbacher, J. C., & Kacena, M. A. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00848-w · Cited by 33
Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización
Etxebarría-Foronda, Í., Caeiro-Rey, J. R., Larrainzar‐Garijo, R., Vaquero-Cervino, E., Roca-Ruiz, L., Mesa-Ramos, M., Pérez, J. M., Carpintero-Benítez, P., Cebrián, A. F., & Gil-Garay, E. (2015) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2015.05.007 · Cited by 39
Chronic systemic inflammation originating from epithelial tissues
Uluçkan, Ö., & Wagner, E. F. (2016) · FEBS Journal · doi:10.1111/febs.13904 · Cited by 31
New insights into treatment of osteoporosis in postmenopausal women
Geusens, P. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000051 · Cited by 28
Taylor, S., Hu, R., Pacheco, E., Locher, K., Pyrah, I., Ominsky, M. S., & Boyce, R. W. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.03.002 · Cited by 25
McClung, M. R., Betah, D., Leder, B. Z., Kendler, D. L., Oates, M. K., Timoshanko, J., & Wang, Z. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae194 · Cited by 26
Self-citationCharacterization of Human Senescent Cell Biomarkers for Clinical Trials
Farr, J. N., Monroe, D. G., Atkinson, E. J., Froemming, M. N., Ruan, M. M., LeBrasseur, N. K., & Khosla, S. (2025) · Aging Cell · doi:10.1111/acel.14489 · Cited by 28
Bone Lining Cells: Normal Physiology and Role in Response to Anabolic Osteoporosis Treatments
Wein, M. N. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0062-x · Cited by 36
Oh, Y. J., Kim, H., Kim, A. J., Ro, H., Chang, J. H., Lee, H. H., Chung, W., Jun, H., & Jung, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103539 · Cited by 25
McCloskey, E. V., Johansson, H., Harvey, N. C., Lorentzon, M., Shi, Y., & Kanis, J. А. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05815-0 · Cited by 26
Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report
Uehara, M., Nakamura, Y., Nakano, M., Miyazaki, A., Suzuki, T., & Takahashi, J. (2021) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxab018 · Cited by 25
Kashii, M., Kamatani, T., Nagayama, Y., Miyama, A., Tsuboi, H., & Ebina, K. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06642-1 · Cited by 25
Tsourdi, E. A., Lademann, F., Ominsky, M. S., Rijntjes, E., Köhrle, J., Misof, B. M., Roschger, P., Klaushofer, K., Hofbauer, L. C., & Rauner, M. (2017) · Endocrinology · doi:10.1210/en.2017-00247 · Cited by 25
Bone Development and Remodeling
Maes, C., & Kronenberg, H. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00060-3 · Cited by 34
Functional Adaptation of Bone: The Mechanostat and Beyond
Pivonka, P., Park, A., & Forwood, M. R. (2017) · Courses and lectures · doi:10.1007/978-3-319-58845-2_1 · Cited by 38
Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease
McDonald, M. M., & Delgado‐Calle, J. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0403-y · Cited by 29
Romosozumab — on track or derailed?
Khosla, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.136 · Cited by 25
Ye, W., Wang, Y., Mei, B., Hou, S., Liu, X., Wu, G., Qin, L., Zhao, K., & Huang, Q. (2018) · Bone · doi:10.1016/j.bone.2018.01.001 · Cited by 25
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
Langdahl, B. L., & Andersen, J. D. (2018) · Journal of Bone Metabolism · doi:10.11005/jbm.2018.25.3.133 · Cited by 25
Self-citationLow Bone Mineral Density in Anorexia Nervosa: Treatments and Challenges
Fazeli, P. K. (2019) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-019-09260-4 · Cited by 28
Current Status of Bone-Forming Therapies for the Management of Osteoporosis
Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00675-8 · Cited by 25
Self-citationThe Role of Bone Biopsy in the Management of CKD-MBD
an initiative of the CKD-MBD working group of the ERA-EDTA the European Renal Osteodystrophy (EUROD), Ferreira, A. C., Cohen-Solal, M. E., D’Haese, P. C., & Ferreira, A. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00838-z · Cited by 25
Menon, V. B., Moysés, R. M. A., Gomes, S. A., Carvalho, A. B., Jorgetti, V., & Heilberg, I. P. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10030913 · Cited by 25
Lessons from rare diseases of cartilage and bone
Gallagher, J. A., Ranganath, L. R., & BOYDE, A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.04.002 · Cited by 26
Cosman, F., Libanati, C. R., Deignan, C., Yu, Z., Wang, Z., Ferrari, S., Jensen, J. B., Peris, P., Bertoldo, F., Lespessailles, É., et al. (2021) · JBMR Plus · doi:10.1002/jbm4.10546 · Cited by 25
Self-citationPositive and Negative Regulators of Sclerostin Expression
Iwamoto, R., Koide, M., Udagawa, N., & Kobayashi, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094895 · Cited by 31
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.